SATELLOS Announces Grant of Stock Options
Satellos Bioscience Announces Grant of Stock Options Toronto, Ontario -- (Newsfile Corp. – June 1,
Satellos Bioscience Announces Grant of Stock Options Toronto, Ontario -- (Newsfile Corp. – June 1,
SATELLOS BIOSCIENCE ANNOUNCES 2023 Q1 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS - $55 million equity financing
Toronto, Ontario -- (Newsfile Corp. – May 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL)
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos’
Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 as a Potential Treatment for Duchenne
Satellos Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model
- SAT-3153 Designated for pre-IND Studies - TORONTO, January 03, 2023 – Satellos Bioscience Inc.
SATELLOS BIOSCIENCE ANNOUNCES Q3 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS TORONTO, November 23, 2022 –
-Proof of concept studies to be completed by YE- TORONTO, November 03, 2022 – Satellos